Business Context and Reporting Period
Company: Gain Therapeutics, Inc. (GANX)
Filing Type: Form 8-K (Current Report)
Date of Report: November 28, 2025
Event: Filing of a prospectus supplement to update an "at-the-market" (ATM) equity offering program.
Key Financial Metrics
This filing does not contain standard financial performance metrics such as revenue, profit, cash flow, or margins. The document focuses exclusively on capital raising activities.
- ATM Program Capacity: Up to $35,530,980.56 of common stock available for sale under the updated prospectus supplement.
- Amount Previously Sold: $14,469,019.44 sold under the prior Distribution Agreement (dated September 6, 2024).
- Sales Agent: Oppenheimer & Co. Inc.
- Underlying Registration: Form S-3 (File No. 333-287622), effective November 26, 2025.
Material Changes
The primary material change is the execution of a new prospectus supplement dated November 28, 2025, which supersedes the previous supplement dated September 6, 2024, regarding the ATM offering. This update allows the Company to continue selling shares under the existing Equity Distribution Agreement up to the specified aggregate limit.
Guidance, Outlook, and Risks
Management Commentary: The filing confirms the validity of the offering through a legal opinion from Lowenstein Sandler LLP. No specific operational guidance or future earnings outlook is provided in this document.
Risks and Contingencies: The filing includes a standard disclaimer stating that the report does not constitute an offer to sell securities in any jurisdiction where such an offer would be unlawful prior to registration or qualification.
Investor Verification Checklist
- Verify the current share price and potential dilution impact of selling up to $35.5 million in additional shares.
- Review the full Prospectus Supplement (dated November 28, 2025) for specific terms of the offering.
- Confirm the Company's current cash position and burn rate to understand the necessity of this capital raise.
- Check for any subsequent filings regarding the actual volume of shares sold under this new supplement.